ECSP044995A - Formulaciones de sucralosa para disimular sabores desagradables - Google Patents

Formulaciones de sucralosa para disimular sabores desagradables

Info

Publication number
ECSP044995A
ECSP044995A EC2004004995A ECSP044995A ECSP044995A EC SP044995 A ECSP044995 A EC SP044995A EC 2004004995 A EC2004004995 A EC 2004004995A EC SP044995 A ECSP044995 A EC SP044995A EC SP044995 A ECSP044995 A EC SP044995A
Authority
EC
Ecuador
Prior art keywords
disagulable
flavors
hidden
medicines
directed
Prior art date
Application number
EC2004004995A
Other languages
English (en)
Inventor
David Jaeger
Jay Dickerson
Annabelle Trimmer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23195896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP044995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP044995A publication Critical patent/ECSP044995A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a una base excipiente líquida farmacéuticamente aceptable para disimular sabor para la administración de una cantidad relativamente amplia de medicinas con sabor desagradable. Más particularmente, se provoca aumentar la dulzura y tener el efecto de disimular el sabor por la adición de sucralosa a la base excipiente con el mantenimiento de un pH de 2 a 5. La invención además está dirigida a composiciones medicinales que comprenden la base excipiente líquida y medicinas con sabor desagradable. Además, la invención se dirige a un método para disimular el sabor desagradable de medicinas a través de su incorporación a las bases excipientes líquidas
EC2004004995A 2001-07-31 2004-02-27 Formulaciones de sucralosa para disimular sabores desagradables ECSP044995A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30891201P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
ECSP044995A true ECSP044995A (es) 2004-04-28

Family

ID=23195896

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004995A ECSP044995A (es) 2001-07-31 2004-02-27 Formulaciones de sucralosa para disimular sabores desagradables

Country Status (13)

Country Link
US (2) US20060121066A1 (es)
EP (1) EP1411955A4 (es)
JP (2) JP2004538309A (es)
AU (1) AU2002324579B2 (es)
BR (1) BR0211794A (es)
CA (1) CA2455939C (es)
CL (1) CL2004000208A1 (es)
CO (1) CO5560580A2 (es)
CR (1) CR7264A (es)
EC (1) ECSP044995A (es)
MX (1) MXPA04001026A (es)
NZ (1) NZ530889A (es)
WO (1) WO2003011306A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
JP2013053136A (ja) * 2011-08-09 2013-03-21 Taisho Pharmaceutical Co Ltd 内服液剤
WO2013084090A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
WO2013088271A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
ES2929945T3 (es) * 2013-11-13 2022-12-05 National Defense Education And Res Foundation Nueva composición de un compuesto de acetaminofeno sin efectos secundarios sobre el hígado
JP6565334B2 (ja) * 2014-06-18 2019-08-28 大正製薬株式会社 固形製剤
CN105640956B (zh) * 2014-11-14 2018-09-14 澳美制药厂有限公司 不含防腐剂的复方磷酸可待因组合口服液及其制备方法
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20160317497A1 (en) * 2015-05-01 2016-11-03 Trinity Ent And Facial Aesthetics Flavored analgesic and decongestant spray
JP6794758B2 (ja) * 2015-10-21 2020-12-02 大正製薬株式会社 経口液体医薬組成物
EP3181150A1 (de) * 2015-12-19 2017-06-21 Analyticon Discovery GmbH Pharmazeutische zubereitungen
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
WO2020251914A2 (en) * 2019-06-09 2020-12-17 DXM Pharmaceutical, Inc. Multi-dose concentrated liquid compositions
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN112439072A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种掩味组合物及其制备方法、用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN117122562A (zh) * 2022-05-21 2023-11-28 山东百诺医药股份有限公司 一种美芬那敏铵口服溶液

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5422508A (en) * 1992-09-21 1995-06-06 Siliconix Incorporated BiCDMOS structure
FI941777L (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
AU706890B2 (en) * 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
JP2000135055A (ja) * 1998-10-29 2000-05-16 Sanei Gen Ffi Inc 乳感の向上した乳含有製品
CN1211085C (zh) * 1999-09-29 2005-07-20 宝洁公司 稳定性改善的组合物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen

Also Published As

Publication number Publication date
CA2455939C (en) 2011-03-22
CL2004000208A1 (es) 2005-03-18
CO5560580A2 (es) 2005-09-30
EP1411955A4 (en) 2006-07-05
JP2010090142A (ja) 2010-04-22
MXPA04001026A (es) 2005-06-20
WO2003011306A1 (en) 2003-02-13
NZ530889A (en) 2005-03-24
CA2455939A1 (en) 2003-02-13
AU2002324579B2 (en) 2007-11-15
US20110136851A1 (en) 2011-06-09
BR0211794A (pt) 2004-11-03
US20060121066A1 (en) 2006-06-08
EP1411955A1 (en) 2004-04-28
JP2004538309A (ja) 2004-12-24
CR7264A (es) 2004-05-17

Similar Documents

Publication Publication Date Title
CR7264A (es) Formulaciones de sucralosa para disimular sabores desagradables
ES2925017T3 (es) Edulcorantes de alta intensidad
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
CN110382007A (zh) 具有恢复的环境效应的组合物的快速和受控递送
WO2006058893A3 (en) Use of diacetyl trimer as an aromatic and flavouring substance
GR20020100506A (el) Φαρμακευτικη συνθεση
BR0308927A (pt) Comprimido mastigável de sabor agradável
AR055329A1 (es) Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
EP1161956A4 (en) DRUG COMPOSITIONS
EP2377557A3 (en) Compositions comprising azelastine and methods of use thereof
SE0102276D0 (sv) Device and method for the administration of a medicament
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
ATE447959T1 (de) Methode zur reduktion des schmerzempfindens
AR025925A1 (es) UNA COMPOSICIoN PARA UNA FORMULACIoN INFANTIL, UN MÉTODO PARA PRODUCIRLA Y SU USO PARA LA FABRICACIoN DE UN MEDICAMENTOS O UN PRODUCTO NUTRICIONAL DIRIGIDO A LA MALNUTRICION.
WO2006063111A3 (en) Pharmaceutical formulations cytidine analogs and derivatives
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
CA2404387A1 (en) Theanine compositions for promoting sleep
EP2845606B1 (en) Medicament for the prevention, curing or abating cough and inflammations of the respiratory system
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
HUP0401592A2 (hu) Modafinilvegyület és ciklodextrin keverékek, eljárás az előállításukra és ezeket tartalmazó készítmények
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
RU2012138581A (ru) Органолептически приемлемая пероральная лекарственная форма ибупрофена и способы ее приготовления и применения
BR0213449A (pt) Comprimido mastigável contendo lisina
ES2186788T3 (es) Utilizacion de oligosacaridos no digestibles en el tratamiento y prevencion de la otitis media en el hombre.
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally